Connect with us

Non classé

Foreign Trade Zones in Today’s Trade Policy Environment

Published

on

Foreign Trade Zones In Today’s Trade Policy Environment

In 1934, when Congress passed the Foreign Trade Zone (FTZ) Act and established the FTZ program, the U.S. economy faced a policy environment similar to today’s: high (and prevalent) tariffs and heightened concern for protecting domestic industries and encouraging domestic investment. Then, as now, policymakers sought mechanisms to help U.S.-based companies stay competitive in the face of escalating costs by offsetting the burden of high tariffs.

For decades, FTZs have been used actively and on trend with overall U.S. import and export statistics, providing importers, exporters, and manufacturers with a toolkit to manage customs duties, streamline operations and bolster cash flow. Today, however, recent tariff actions on steel and aluminum that for most countries doubled to 50% under Section 232 of the Trade Expansion Act of 1962, as well as sweeping International Emergency Economic Powers Act (IEEPA) reciprocal tariffs imposed on nearly all commodities from all countries, have upended global trade and shifted the FTZ landscape significantly.

As trade tensions push import duties to record highs, companies big and small are looking for ways to insulate themselves against tariff volatility and stabilize cash flow against economic uncertainty. While FTZs are resonating as a strategy to mitigate or avoid absorbing higher tariffs into operating costs, the program is not a silver bullet. Instead, FTZ participation in 2025 demands a more nuanced cost-benefit analysis that weighs the traditional advantages of FTZs compared to the current benefits against changing trade policy.

Traditional FTZ Benefits

Licensed by the U.S. FTZ Board, FTZs are secure, designated sites traditionally located within 60 miles or a 90-minute drive from a U.S. port of entry (although FTZ sites now are often located at further points as well), in which domestic and foreign merchandise (i.e., inventory) receives the same treatment by U.S. Customs and Border Protection (CBP) as if it were outside the commerce of the United States. FTZs enable companies to defer, reduce or eliminate duties, depending on where goods end up (e.g., distributed domestically or exported to avoid applicable duties and taxes).

Historically, one of the most important FTZ benefits was inverted tariff relief for manufacturers. Through the Boggs Amendment of 1950 and regulatory clarifications in the 1980s, U.S. manufacturers could import higher-duty inputs, process them domestically, and release finished products into the commerce of the U.S. at lower duty rates of the finished products. This helped manufacturers reduce overall tariff costs, enhance profitability and get on more even footing with offshore manufacturers.

Put another way, it gave U.S.-based businesses federal approval to rationalize what historically was “irrational tariff treatment” in the Harmonized Tariff Schedule of the U.S. (HTSUS). Irrational tariff treatment is when imported parts and materials are assessed at higher duty rates than the finished goods they are incorporated into. Without the ability to invert duty rates, companies would be financially incentivized, from a customs duty treatment perspective, to import finished goods rather than produce them domestically.

Beyond inverted tariffs, FTZs offer additional benefits:

Export relief: Goods brought in and stored or manufactured in an FTZ can be exported in bond without incurring quota charges or U.S. duties, insulating businesses from the adverse effects of tariff hikes. Plus, merchandise exported from FTZs to international customers and subsequently returned can be admitted to an FTZ for storage, repair and export again without being subject to duties.

Cash-flow benefits: The timing of when duties are paid makes a significant difference to cash flow. By deferring the payment of duties until goods leave an FTZ, companies improve working capital. By bringing the duty cost closer to when goods are sold to the customer, companies can shorten the cash cycle and optimize cash flow. Depending on how fast a business turns its inventory, this can be a critical part of a company’s ability to maintain its U.S. operations.

Weekly customs entry and Merchandise Processing Fee (MPF) savings: MPF is paid per customs entry (.3464% against the value reported on the entry) but has a maximum amount today of $651.50 with routine incremental increases each year. However, FTZs permit qualified companies to consolidate an entire week’s worth of shipments out of the FTZ into a single weekly customs entry, thereby creating the opportunity to possibly save broker entry fees and significantly reduce annual MPF spend. Filing consolidated weekly entries is especially appealing for high-volume importers but comes with its own set of complexities in the current trade policy environment.

State and local tax savings: In states that assess ad valorem tax on inventory, such as Texas, Kentucky, Louisiana and Puerto Rico, inventory held in FTZs may be preempted from such taxes through the federal FTZ law. Likewise, some states have codified state-level tax benefits, such as Arizona’s reduction of up to 75% for real and personal property held in FTZs. These tax exemptions and reductions—above and beyond the traditional duty benefits of the program—create additional financial incentives and help further reduce operational costs for FTZ users.

A Changing Trade Landscape

For decades, these advantages attracted a diverse mix of manufacturers and distributors into the program. In 2018, however, key tariff developments began to disrupt the global trade landscape. In January 2018, the U.S. imposed safeguard tariffs on solar panels and washing machines from all sources (except Canada) under Section 201 of the Trade Act of 1974. In March 2018, Section 232 tariffs on steel and aluminum took effect, with temporary exemptions for Canada, Mexico, Australia, Argentina, Brazil, South Korea and the EU. By June, however, exemptions had expired for Canada, Mexico and the EU, and Section 232 tariffs were imposed.

In April 2018, the U.S. Trade Representative (USTR) released a list of 1,333 China-origin imports for proposed 25% Section 301 duties, as part of a broader and new trading strategy with the East Asian nation. Within days, China imposed retaliatory tariffs of its own on U.S. exports. By June, the USTR proposed a new list of products from China, worth $50 billion in trade, to be subject to Section 301 duties of 25%. These initial trade remedy actions in 2018 were just the beginning of what is now an almost eight-year-long, increasingly complicated but fundamental change in U.S. trade policy.

Interestingly, with the first six months of 2018 also came a pivotal shift in how FTZs function today: a change to mandating the election of Privileged Foreign (PF) status for imported merchandise at the time of admission to an FTZ, which locks in an item’s classification and duty rate on that date. For decades, imported raw materials, components and finished goods were largely admitted into FTZs in Non-privileged Foreign (NPF) status, which requires classification on the item’s condition as removed from the FTZ at the duty rate in effect on the date of entry. For FTZ manufacturers authorized by the U.S. Department of Commerce, NPF status elected for imported parts and components is what drove inverted tariff benefit (i.e., the ability to apply the finished good duty rate to the value of the parts/components consumed in the finished good). With 2018’s new tariff actions, the Administration through the U.S. Trade Representative and the U.S. Department of Commerce began requiring FTZ imports to be admitted in PF status. PF status “locks in” the normal, or Most Favored Nation (MFN), duties and any remedy tariff rates on goods at the time of their admission into an FTZ, which means the imported component’s duty and tariff rates apply even if the finished good made in the FTZ carries a lower duty rate.

What does this mean in practical terms? It means the inverted tariff benefit for FTZ manufacturers was essentially eliminated in April of this year when the PF status admission stipulation began applying to nearly all imported commodities from all countries of origin via IEEPA reciprocal tariffs. Now, existing FTZ manufacturers as well as manufacturers considering the program must recalculate the savings opportunities from FTZ usage. For some manufacturers, the program may continue to make sense or drive even more benefit, while for others the program may no longer make sense. Paradoxically, tariffs intended to protect U.S. jobs are simultaneously hampering some FTZ manufacturers from promoting domestic production, the original intent of the program. If the same finished product is made in another country, under IEEPA reciprocal tariffs, it still offers a lower overall tariff rate when imported than the imported parts and components used to make the finished product in the U.S. If the goal of current trade policy, however, is to reshore and nearshore manufacturing, don’t FTZ manufacturers still need the inverted tariff benefit to rationalize what is otherwise still an irrational HTSUS?

FTZ Advantages Today

What are the main advantages for FTZ users today then? For many importers, it’s cash flow: by delaying duty payments, companies can preserve capital. This benefit, however, depends heavily on inventory turnover. Large retailers cross-docking goods through distribution centers may realize little advantage as goods enter U.S. commerce within days, triggering prompt duty payments. By contrast, businesses holding inventory for weeks or months can extract more meaningful benefit from duty deferral, such as industrial distributors, seasonal retailers, or exporters awaiting foreign buyers.

In the absence of inverted tariffs, the importance of export relief has grown. Manufacturers that ship even a portion of their production abroad can typically eliminate duties altogether on exported goods. For many businesses that traditionally relied on inverted tariffs, this now represents one of the few clear savings opportunities. Additionally, some manufacturers that previously had little reason to consider FTZs are now compelled to join the program precisely to avoid duties on outbound shipments.

While tariff relief is the focus for many, ancillary benefits remain material. Although now more administratively complex, weekly entry/MPF savings continue to appeal to some while the compliance requirements may outweigh the fee savings for others. Inventory and real/personal property tax abatements are still available in states such as Texas, Kentucky, Louisiana, Arizona and Puerto Rico, but these benefits are not guaranteed. They require negotiation with local impacted tax recipients and cannot be assumed across the board. Companies that install imported production equipment in their FTZ production facilities can also achieve duty/tariff deferral benefits on the machinery until it begins being using in production.

Looking Ahead: Uncertainty and Opportunity

The FTZ program is at a crossroads. Its historical role as an engine for tariff rationalization for U.S. manufacturers has been curtailed, but its potential as a platform for cash flow management, export relief and targeted ancillary tax savings is legitimate. In addition, pending litigation, including possible Supreme Court rulings, could dramatically reshape the tariff landscape overnight. A rollback of tariffs could potentially restore inverted tariff benefits for many industries and commodities, while new tariff exemption frameworks could offer parallel relief.

For importers and manufacturers, the shift in trade policy has forced more sophisticated supply chain analyses. Establishing and operating an FTZ requires significant time and investment in an extremely complex trade compliance environment. Understanding if setting up and operating an FTZ makes sense in the context of this complexity is not a simple exercise. For tax and finance professionals, determining whether FTZ participation will yield measurable benefit requires a more granular assessment of inventory turn rates and export volumes. Companies must model turnover rates, tariff exposures, and compliance costs in detail to decide whether an FTZ is advantageous for the organization’s unique product mix, trade patterns, and risk tolerance.

Parting Thoughts

For businesses, agility is critical. Companies must reassess FTZ participation regularly, model cash flow implications under various scenarios, and assess measures for ancillary benefits, including engaging with local authorities on property and inventory tax opportunities where appropriate.

For policymakers grappling with the challenge of reconciling tariff policy with industrial strategy, FTZs may represent an underused tool. In an era when tariff policies are used both as protectionist levers and geopolitical instruments, FTZs provide a stable, regulated framework for balancing trade governance with competitiveness.

FTZs are not loopholes. They are highly regulated, overseen by U.S. CBP and the Department of Commerce, and subject to annual reviews and public interest considerations for manufacturers. In many ways, they are better suited to provide equitable tariff mitigation than ad hoc exemption processes. A 2019 econometric study conducted by The Trade Partnership titled The U.S. Foreign-Trade Zones Program: Economic Benefits to American Communities quantified that—all else being equal—employment, wages, and value-added activity are higher in areas with FTZs than similar areas without FTZs, and that a company’s access to FTZ benefits has substantial positive ripple effects throughout its U.S. supply chain.

And so, as they were conceived, FTZs are an effective mechanism for encouraging domestic manufacturing and facilitating global competitiveness.

By Rebecca Williams, Managing Director, Rockefeller Group Foreign Trade Zone Services and Eric Dalby, VP Support, Professional Services at Descartes

The post Foreign Trade Zones in Today’s Trade Policy Environment appeared first on Logistics Viewpoints.

Continue Reading

Non classé

Supply Chain KPIs Are No Longer Keeping Up with the Job

Published

on

By

Supply chain leaders are being asked to deliver far more than cost savings. They are expected to improve resilience, accelerate decisions, manage supplier risk, strengthen continuity, and support broader business strategy. Yet in many organizations, the performance metrics used to evaluate supply chain teams still reflect an older operating model built primarily around savings and transactional efficiency.

That gap matters. If the work has expanded but the scorecard has not, teams may be incentivized to optimize for short-term cost reductions while underweighting resilience, responsiveness, and risk readiness. Supplier diversification, recovery planning, sourcing cycle time, decision latency, and exposure visibility are increasingly central to supply chain performance, but they are not always captured in traditional KPI frameworks.

The Institute for Supply Management recently published a useful article on this issue, arguing that supply chain value now needs to be measured across a broader set of dimensions, including resilience, speed, risk reduction, and organizational readiness. The piece makes the case that savings remain important, but they are no longer sufficient as the primary indicator of supply chain contribution.

For supply chain executives, the larger takeaway is clear: measurement systems need to catch up with the strategic role supply chain now plays. Organizations that modernize their KPI frameworks will be better positioned to demonstrate value not only through cost control, but through continuity, agility, and better enterprise decision-making.

Read the full article from the Institute for Supply Management here: Supply Chain work has evolved faster than the KPI’s used to measure it.

The post Supply Chain KPIs Are No Longer Keeping Up with the Job appeared first on Logistics Viewpoints.

Continue Reading

Non classé

Why Regulated Supply Chains Are Prioritizing Traceability Over Pure Efficiency

Published

on

By

For decades, supply chain strategy was dominated by efficiency. Companies reduced inventory, consolidated suppliers, optimized transportation networks, minimized operational slack, and extended global sourcing structures in pursuit of lower costs and better asset utilization.

Those priorities still matter. But in regulated industries, they are no longer enough.

Healthcare, pharmaceuticals, aerospace, food, and medical-device supply chains now operate under a broader definition of performance. Product accountability, traceability, compliance continuity, and operational control are becoming as important as traditional efficiency metrics. In these sectors, the supply chain is not simply a cost structure. It is part of the organization’s control system.

That is why traceability is moving from an administrative requirement to a strategic operating capability. It allows companies to understand where materials originated, how products moved, which lots were affected, where inventory was distributed, and which customers or facilities received product. In stable conditions, that information may appear routine. Under disruption, it becomes essential.

Efficiency Alone Can Create Fragility

Highly optimized supply chains can perform very well when conditions are stable. The problem emerges when something goes wrong.

A supplier issue, quality deviation, transportation disruption, documentation failure, or traceability gap can quickly create consequences that extend far beyond delayed delivery. In regulated environments, these failures may trigger investigations, product holds, recalls, compliance exposure, customer disruption, and reputational damage.

That changes the operating calculus. A supply chain optimized purely for cost may not provide enough visibility or control when conditions deteriorate. The result is a shift toward a more balanced view of operational performance.

The objective is no longer simply maximum efficiency. It is controlled resilience.

Traceability Is More Than Compliance

Traceability is often treated narrowly as a compliance requirement. Its strategic value is broader.

Strong traceability improves root-cause analysis. It strengthens recall precision. It supports supplier accountability. It reduces ambiguity during disruptions. It helps organizations isolate operational risk more quickly and respond with greater confidence.

In practice, traceability becomes part of the enterprise’s ability to operate under uncertainty. A supply chain that clearly understands its dependencies can respond more intelligently than one relying on fragmented records, manual investigation, and disconnected documentation.

This is especially important in industries where the cost of ambiguity is high. In food, a traceability gap can widen the scope of a recall. In pharmaceuticals, incomplete lot visibility can delay containment. In aerospace or medical devices, documentation failures can affect audit readiness, quality assurance, and customer trust.

The strategic point is straightforward: traceability is not just about knowing what happened. It is about being able to act when it matters.

Complexity Is Raising the Bar

Several forces are increasing traceability requirements across regulated industries. Global sourcing networks are longer and more complex. Product portfolios are becoming more specialized. Regulatory scrutiny continues to increase. ESG expectations are adding new accountability pressures. Serialization, product authentication, and chain-of-custody requirements are expanding.

At the same time, supply chains are becoming more digital. Sensor data, IoT monitoring, electronic batch records, serialization systems, digital quality environments, supplier platforms, and logistics visibility tools now generate far more operational information than before.

The challenge is no longer simply collecting data. The challenge is coordinating and interpreting it across the enterprise.

That requires stronger data governance, better integration, and more contextual intelligence. Traceability systems create limited value if the data remains trapped in separate systems or disconnected from operational decision-making.

Traceability Depends on Coordination

A quality alert matters only if the organization can quickly identify affected inventory. A supplier issue matters only if downstream dependencies are visible. A transportation disruption matters only if customer, inventory, and compliance implications can be understood quickly.

This is where the broader shift toward continuous intelligence becomes important. As discussed in The Next Supply Chain Operating Model Will Be Built Around Continuous Intelligence, supply chains increasingly require systems capable of sensing, interpreting, and coordinating operational response continuously.

Traceability becomes significantly more valuable when it supports faster and more coordinated decisions. It is not enough to document product movement after the fact. Companies need traceability data to inform decisions in near real time.

This also explains why graph-oriented architectures and contextual AI systems are attracting attention. Regulated supply chain risk rarely exists in isolation. It moves through relationships among suppliers, products, lots, facilities, customers, logistics flows, and regulatory obligations.

Understanding those relationships operationally is becoming increasingly important.

The Efficiency Tradeoff Is Becoming More Nuanced

Prioritizing traceability does not mean abandoning efficiency. It means recognizing that efficiency must be balanced against resilience, accountability, and operational control.

The most efficient network on paper may not be the most resilient network under stress. A lower-cost supplier strategy may create greater exposure if visibility is weak. A highly optimized transportation network may become vulnerable if traceability and exception response are insufficient.

This does not eliminate the importance of lean operations. It changes the definition of operational maturity.

The organizations that perform best increasingly understand where visibility, traceability, and control create disproportionate strategic value. They are not simply asking how to reduce cost. They are asking where lack of control could create unacceptable operational, regulatory, or reputational exposure.

The Strategic Implication

Regulated supply chains are moving toward a broader definition of operational excellence.

Cost and efficiency still matter. But so do traceability, governed response, compliance continuity, visibility, accountability, and operational resilience.

The organizations that lead over the next decade may not simply be those with the lowest cost structures. They may be the ones capable of maintaining control, preserving trust, and coordinating response effectively under increasingly complex operating conditions.

In regulated industries, traceability is no longer merely administrative infrastructure. It is becoming part of the competitive operating model itself.

The post Why Regulated Supply Chains Are Prioritizing Traceability Over Pure Efficiency appeared first on Logistics Viewpoints.

Continue Reading

Non classé

Medtronic: Strengthening Regulated Medical Device Supply Chains

Published

on

By

Medical device supply chains operate under a different standard than many commercial supply chains.

Efficiency still matters. So do inventory discipline, transportation performance, and cost control. But regulated healthcare environments must also preserve traceability, quality assurance, compliance continuity, documentation integrity, product accountability, and controlled response processes.

That changes the operating model.

Medtronic offers a useful example. As one of the world’s largest medical technology companies, it operates across a complex global network of manufacturing sites, suppliers, logistics providers, hospitals, clinicians, distributors, regulators, and field-service organizations.

The objective is not simply to move products efficiently. It is to maintain product availability, quality, traceability, and regulatory compliance at the same time.

Regulation Changes the Supply Chain Equation

In many industries, supply chain performance is measured primarily through cost, service, and working-capital efficiency.

In regulated healthcare, the equation is broader. A shipment delay matters, but so does a documentation error, labeling issue, quality deviation, traceability gap, supplier compliance problem, or uncontrolled product movement.

The consequences can extend well beyond logistics disruption. They may affect regulatory exposure, product release, recall management, or clinical continuity.

That changes how resilience is defined. In regulated supply chains, resilience is not simply the ability to move inventory around disruption. It is the ability to preserve continuity while maintaining quality, traceability, and compliance discipline throughout the process.

That is a more demanding operating requirement.

Visibility Must Extend Beyond Transportation

For medical device companies, visibility cannot stop at shipment tracking.

The enterprise also needs visibility into supplier quality, serialized inventory, manufacturing conditions, product genealogy, service inventory, documentation status, field inventory positioning, and regulatory workflows.

The supply chain is not merely transporting products. It is managing accountable product movement across a controlled operating environment.

This is why regulated industries are investing more heavily in integrated visibility and traceability systems. Companies need to know not only where products are, but whether they remain compliant, whether documentation is complete, whether quality conditions have been maintained, and whether downstream commitments remain protected.

That requires tighter coordination across supply chain, quality, manufacturing, logistics, and regulatory functions.

Exception Management Becomes More Sensitive

Exceptions carry greater operational consequence in regulated healthcare environments.

A delayed shipment may affect hospital inventory. A supplier issue may trigger quality review. A labeling problem may delay product release. A traceability gap may complicate recall management.

The organization therefore needs more than awareness. It needs governed response.

This connects directly to the broader rise of autonomous exception management in logistics operations. In regulated supply chains, earlier detection is valuable not only because it accelerates response, but because it gives the enterprise more time to coordinate a compliant response before risk escalates.

AI-assisted systems may help prioritize exceptions, assemble context, identify affected inventory, and route decisions more efficiently. But the operating environment still requires governance, escalation controls, auditability, and human oversight.

This is not uncontrolled automation. It is governed operational intelligence.

Coordination Across the Enterprise

Medical device supply chains are deeply interconnected.

Supply chain teams must coordinate continuously with manufacturing, procurement, quality, regulatory, logistics, commercial teams, field-service operations, and healthcare providers. A disruption in one part of the network can quickly propagate into others.

That is why fragmented systems create particular risk in regulated industries. Disconnected operational environments do not merely reduce efficiency. They can increase operational and compliance exposure at the same time.

For medical device companies, enterprise coordination is not a process improvement exercise. It is part of the control system that protects product integrity, customer commitments, and regulatory standing.

The Broader Lesson

Medtronic’s operating environment reflects a broader shift across regulated industries.

The future supply chain is not simply leaner or faster. It must also be more traceable, more coordinated, more governed, more resilient, and more transparent.

That requires stronger integration between supply chain execution, quality management, regulatory processes, and enterprise intelligence systems.

In regulated healthcare, the supply chain is becoming part of the trust architecture surrounding the product itself. Over the next decade, that may become one of the most important strategic operating requirements in the industry.

The post Medtronic: Strengthening Regulated Medical Device Supply Chains appeared first on Logistics Viewpoints.

Continue Reading

Trending